Active Ingredient(s): Rucaparib
FDA Approved: * December 19, 2016
Pharm Company: * Clovis Oncology, Inc.
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rubraca Overview

Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is approved in the United States and in Europe as third line treatment in BRCA-mutated ovarian cancer.[3][4][5] It can be taken orally in tablet form.[2][6] The most common side effects include ti...

Read more Rubraca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Rubraca Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 200mg, 250mg, 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rubraca: (3 results)

Sorted by National Drug Code
  • 69660-201 Rubraca 200 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.
  • 69660-202 Rubraca 250 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.
  • 69660-203 Rubraca 300 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.

Other drugs which contain Rucaparib or a similar ingredient: (1 result)